Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. in a bid to boost its drug ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Novartis AG (NVS) has made a takeover approach for San Diego-headquartered Avidity Biosciences (RNA), Financial Times reported on Wednesday, citing people familiar with the matter. Novartis has been ...

We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, ...

Glencore maintains its UK listing; Britain seeks clarity on China's embassy plans; Novartis considers acquiring biotech firm ...

Shares of Dyne Therapeutics ( NASDAQ: DYN ), a competitor to Avidity ( NASDAQ: RNA ), also jumped 7.5% on news of the Novartis ( NYSE: NVS) approach. Avidity focused on developing Antibody ...